{
    "id": "35cd2705-eb39-aaaa-e063-6294a90a66c9",
    "indications": {
        "text": "fotivda indicated treatment adult patients relapsed refractory advanced renal cell carcinoma ( rcc ) following two prior systemic therapies .",
        "doid_entities": [
            {
                "text": "renal cell carcinoma (DOID:4450)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4450"
            },
            {
                "text": "carcinoma (DOID:305)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_305"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "recommended dose : 1.34 mg daily without food 21 days treatment followed 7 days treatment ( 28-day cycle ) disease progression unacceptable toxicity . ( 2.1 ) dose interruptions and/or dose reduction may needed manage . ( 2.2 ) patients moderate hepatic impairment , reduce dose 0.89 mg 21 days treatment followed 7 days treatment ( 28-day cycle ) . ( 2.3 )",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "adverseReactions": "none .",
    "ingredients": [
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "TIVOZANIB HYDROCHLORIDE",
            "code": "8A9H4VK35Z",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_91327"
        }
    ],
    "organization": "AVEO Pharmaceuticals, Inc.",
    "name": "FOTIVDA",
    "effectiveTime": "20250523",
    "indications_original": "FOTIVDA is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.",
    "contraindications_original": "Recommended Dose: 1.34 mg once daily with or without food for 21 days on treatment followed by 7 days off treatment (28-day cycle) until disease progression or unacceptable toxicity. ( 2.1 ) Dose interruptions and/or dose reduction may be needed to manage adverse reactions. ( 2.2 ) For patients with moderate hepatic impairment, reduce the dose to 0.89 mg for 21 days on treatment followed by 7 days off treatment (28-day cycle). ( 2.3 )",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "FOTIVDA",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        }
    ]
}